A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study

Stovner, Lars Jacob; Linde, Mattias; Gravdahl, Gøril Bruvik; Tronvik, Erling; Aamodt, Anne Hege; Sand, Trond; Hagen, Knut

doi:10.1177/0333102413515348

Cited by 138 publications

(106 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35 Candesartan was noninferior to propranolol. The proportion of responders was significantly higher on candesartan (43%) and propranolol (40%) than on placebo (23%) (PG.025 and PG.050, respectively).…”

Section: Other Drugs For the Prevention Of Migrainementioning

confidence: 98%

Preventive Migraine Treatment

Silberstein

2015

CONTINUUM: Lifelong Learning in Neurology

180

211

View full text Add to dashboard Cite

Purpose of Review: This article reviews the evidence base for the preventive treatment of migraine. Recent Findings: Evidence-based guidelines for the preventive treatment of migraine have recently been published by the American Academy of Neurology (AAN) and the Canadian Headache Society (CHS), providing valuable guidance for clinicians. Strong evidence exists to support the use of metoprolol, timolol, propranolol, divalproex sodium, sodium valproate, and topiramate for migraine prevention, according to the AAN. Based on best available evidence, adverse event profile, and expert consensus, topiramate, propranolol, nadolol, metoprolol, amitriptyline, gabapentin, candesartan, Petasites (butterbur), riboflavin, coenzyme Q10, and magnesium citrate received a strong recommendation for use from the CHS. Summary: Migraine preventive drug treatments are underutilized in clinical practice. Principles of preventive treatment are important to improve compliance, minimize side effects, and improve patient outcomes. Choice of preventive treatment of migraine should be based on the presence of comorbid and coexistent illness, patient preference, reproductive potential and planning, and best available evidence.

show abstract

Section: Other Drugs For the Prevention Of Migrainementioning

confidence: 98%

Preventive Migraine Treatment

Silberstein

2015

CONTINUUM: Lifelong Learning in Neurology

180

211

View full text Add to dashboard Cite

show abstract

“…The calcium channel blocker flunarizine may be helpful [Diener et al 2002], and anecdotally is said to be the drug of choice for patients with prolonged aura, hemiplegic attack or prominent vertigo. There is also increasing evidence that angiotensin blockers such as candesartan are useful and well tolerated in migraine prevention [Tronvik et al 2003;Stovner et al 2013]. Details of dose regimes are given in Table 1. If first-or second-line preventives fail, the patient should be referred to a specialist headache clinic for reevaluation, and consideration of nonpharmacological interventions such as greater occipital nerve blocks (case series suggest this may be useful in reducing headache frequency and severity for a limited period in over 50% of patients [Afridi et al 2006], though a recent double-blind randomized controlled trial casts doubt on this [Dilli et al 2014]) or Botox (onabotulinum toxin A; Allergan, Irvine, CA) injections for chronic migraine (two successive sets of injections of 155-195 U in seven areas of the head and neck having been shown to reduce headache days by 50% over 6 months in such patients) [Aurora et al 2011].…”

Section: Preventive Treatmentmentioning

confidence: 99%

The diagnosis and treatment of chronic migraine

Weatherall

2015

Therapeutic Advances in Chronic Disease

134

View full text Add to dashboard Cite

Abstract:Migraine is the most common disabling brain disorder. Chronic migraine, a condition characterized by the experience of migrainous headache on at least 15 days per month, is highly disabling. Patients with chronic migraine present to primary care, are often referred for management to secondary care, and make up a large proportion of patients in specialist headache clinics. Many patients with chronic migraine also have medication overuse, defined as using a compound analgesic, opioid, triptan or ergot derivative on at least 10 days per month. All doctors will encounter patients with chronic headaches. A basic working knowledge of the common primary headaches, and a rational manner of approaching the patient with these conditions, allows a specific diagnosis of chronic migraine to be made quickly and safely, and by making this diagnosis one opens up a substantial number of acute and preventive treatment options. This article discusses the current state of management of chronic migraine.

show abstract

“…Angiotensin I-converting enzyme is thought to be involved in blood pressure control and vascular tension; both angiotensin converting enzyme inhibitors and angiotension II receptor blockers have shown efficacy for migraine prevention. 17,18 The possible association between migraine with aura and elevated angiotensin-converting enzyme levels due Hypertension and Migraine -Gardener et al continued control of hypertension.…”

Section: Hypertension and Migraine -Gardener Et Almentioning

confidence: 99%